Pfizer Price Target Raised to $35.00/Share From $33.00 by Scotiabank

What happened

Scotiabank raised its price target for Pfizer to $35.00 per share from $33.00 per share. It maintained its Sector Outperform rating on the company, according to the supplied ratings-action report.

Confirmed

Global impact / market context

A higher price target signals that Scotiabank sees more potential value in Pfizer shares than before, while keeping its favorable rating. If investors act on that view, share demand could rise, but the report gives no new information about Pfizer’s sales, costs, or cash available.

Analyst inference

This is an analyst opinion update, not a reported change in Pfizer’s business or a confirmed shift in its financial outlook. The target moves from $33.00 to $35.00 per share, but the supplied report gives no explanation, timing, or expected effect on company results.

Analyst inference

What to watch

1. Check for a later explanation from Scotiabank about what prompted the higher target; the supplied ratings action provides no reasoning or financial assumptions. Analyst inference
2. Look for further analyst rating changes on Pfizer, as agreement or disagreement could influence investor expectations and trading demand for its shares. Analyst inference
3. Compare future company updates on sales, costs, and cash available with analyst expectations to see whether business results support the higher target. Analyst inference

Evidence

• Original source link unavailable